The influence of HER2 genotypes as molecular markers in ovarian cancer outcome

• Type: Article in International Scientific Journal
• Date: 2005

Authors

Pinto, D (Author) Other; Pereira, D (Author) Other; Portela, C (Author) Other; da Silva, JL (Author) Other; Carlos, LA (Author) Other; Medeiros, R (Author) ICBAS

Journal

Title: Biochemical and Biophysical Research Communications

Vol. 335

Pages: 1173-1178

ISSN: 0006-291X

Publisher: Elsevier

Indexing

ISI Web of Knowledge - 29 Citations

Scopus - 29 Citations

Scientific classification

FOS: Natural sciences > Biological sciences

Other information

Authenticus ID: P-000-0YF

DOI: 10.1016/j.bbrc.2005.08.012

Abstract (EN): A relevant clinical problem in the treatment of ovarian cancer (OC) is the development of resistance to chemotherapy, frequently due to genetic variations in enzymes and receptors. Changes in the HER2 receptor have been associated with breast and ovarian cancers. The role of a polymorphism in the HER2 gene in the clinical outcome of OC patients was investigated in this study. We characterized DNA samples from 111 patients with OC treated with cisplatin and paclitaxel, using PCR-RFLP. Our results indicate that patients carrying the valine homozygotic genotype present a lower overall survival mean, suggesting a role for this polymorphism in the outcome of ovarian cancer patients. The G allele has been implicated in the formation of active HER2 receptors, with a more aggressive phenotype. We hypothesize that HER2 genotypes can be predictive biomarkers in ovarian cancer, contributing to a genetic individual profile of great interest in clinical oncology.

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 6